Ligand id: 9132

Name: vanucizumab

Compound class Antibody
International Nonproprietary Names
INN number INN
9950 vanucizumab
RG-7221 | RG7221 | RO5520985
Vanucizumab is an investigational bi-specific monoclonal antibody, with potential anti-neoplastic activity being developed by Hoffmann-La Roche [1-2]. Vanucizumab simultaneously targets angiopoietin 2 (ANGPT2) and vascular endothelial growth factor A (VEGFA).
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. BLAST seuqence analysis reveals 100% matches with peptide sequences claimed in patent US8945552 and likely identify XMab1 and XMab2 as candidates for vanucizumab [1].
Database Links
Specialist databases
IMGT/mAb-DB 500
Other databases
GtoPdb PubChem SID 315661217
Search PubMed clinical trials vanucizumab
Search PubMed titles vanucizumab
Search PubMed titles/abstracts vanucizumab